Exploring the Preferences of the Australian Public for Antibiotic Treatments: A Discrete Choice Experiment.


Journal

The patient
ISSN: 1178-1661
Titre abrégé: Patient
Pays: New Zealand
ID NLM: 101309314

Informations de publication

Date de publication:
09 2023
Historique:
accepted: 21 06 2023
medline: 9 8 2023
pubmed: 18 7 2023
entrez: 18 7 2023
Statut: ppublish

Résumé

Identify Australian public preferences for antibiotic treatments in the context of antibiotic stewardship. A discrete choice experiment (DCE) was conducted in Australia to investigate the importance of seven attributes associated with antibiotic treatments and related stewardship practices: contribution to antimicrobial resistance (AMR), treatment duration, side effects, days needed to recover, days before taking antibiotics, treatment failure and out-of-pocket costs. The DCE data were analysed using conditional logit, mixed logit and latent class conditional logit models. The relative importance of each attribute was calculated. A total of 1882 respondents completed the survey; the main study sample consist of 1658 respondents (mean age 48 years) who passed quality checks. All seven attributes significantly influenced respondents' preferences for antibiotic treatments. Based on the designed attribute levels in the DCE, on average, out-of-pocket costs (32.8%) and contribution to antibiotic resistance (30.3%) were the most important attributes, followed by side effects (12.9%). Days before starting medication was least important (3.9%). Three latent classes were identified. Class 1 (including respondents who were more likely to be older and more health literate; 24.5%) gave contribution to antibiotic resistance greater importance in treatment preferences. Class 2 (including respondents more likely to report poorer health; 25.2%) gave out-of-pocket costs greater importance. The remaining (50.4%), who were generally healthier, perceived side effects as the most important attribute. Despite concerted public awareness raising campaigns, our results suggest that several factors may influence the preferences of Australians when considering antibiotic use. However, for those more likely to be aware of the need to preserve antibiotics, out-of-pocket costs and limiting the contribution to antibiotic resistance are the dominant influence. Delays in starting treatment were not important for any latent class, suggesting public tolerance for this measure. These results could help inform strategies to promote prudent antibiotic stewardship.

Identifiants

pubmed: 37462880
doi: 10.1007/s40271-023-00640-z
pii: 10.1007/s40271-023-00640-z
pmc: PMC10409829
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

555-567

Informations de copyright

© 2023. The Author(s).

Références

PLoS One. 2018 Oct 24;13(10):e0204878
pubmed: 30356302
Health Promot Int. 2007 Mar;22(1):53-64
pubmed: 17046966
Lancet. 2023 Dec 17;400(10369):2221-2248
pubmed: 36423648
Value Health. 2011 Jun;14(4):403-13
pubmed: 21669364
Antibiotics (Basel). 2018 Nov 01;7(4):
pubmed: 30388824
J Glob Infect Dis. 2019 Jan-Mar;11(1):36-42
pubmed: 30814834
Scand J Prim Health Care. 2022 Mar;40(1):95-103
pubmed: 35166180
Lancet Reg Health West Pac. 2022 Jul 07;27:100521
pubmed: 35832237
BMJ Open. 2020 Sep 17;10(9):e037884
pubmed: 32948565
Lancet Infect Dis. 2010 Mar;10(3):167-75
pubmed: 20185095
Soc Sci Med. 2022 Jul;305:115033
pubmed: 35617765
Int J Public Health. 2010 Oct;55(5):469-78
pubmed: 20603713
Lancet Infect Dis. 2013 Dec;13(12):1057-98
pubmed: 24252483
PLoS One. 2022 Jan 14;17(1):e0261917
pubmed: 35030191
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Pharmacoeconomics. 2008;26(8):661-77
pubmed: 18620460
Pharmacoepidemiol Drug Saf. 2015 Jan;24(1):2-10
pubmed: 25251203
J Antimicrob Chemother. 2016 Jan;71(1):27-33
pubmed: 26459555
Health Econ. 2012 Feb;21(2):145-72
pubmed: 22223558
PLoS Med. 2021 Aug 30;18(8):e1003737
pubmed: 34460825
BMC Public Health. 2017 Oct 10;17(1):799
pubmed: 29017473
Int J Antimicrob Agents. 2020 Dec;56(6):106198
pubmed: 33080314
Clin Microbiol Infect. 2019 Jan;25(1):48-53
pubmed: 29777927
Aust Fam Physician. 2016 Sep;45(9):688-90
pubmed: 27606375
Lancet. 2020 Jan 18;395(10219):200-211
pubmed: 31954465
Bull World Health Organ. 2017 Nov 1;95(11):764-773
pubmed: 29147057

Auteurs

Chris Degeling (C)

Australian Centre for Health Engagement Evidence and Values, University of Wollongong, Wollongong, NSW, 2522, Australia. degeling@uow.edu.au.

Trent Yarwood (T)

Cairns and Hinterland Hospital and Health Service, Cairns, QLD, Australia.
Cairns Clinical School, College of Medicine and Dentistry, James Cook University, Townsville, Australia.
Rural Clinical School, Faculty of Medicine, University of Queensland, Brisbane, Australia.

Alberto Nettel-Aguirre (A)

Centre for Health and Social Analytics, University of Wollongong, NIASRA, Wollongong, NSW, 2522, Australia.

Judy Mullan (J)

Graduate School of Medicine, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW, Australia.

Nina Reynolds (N)

School of Business, Faculty of Business and Law, University of Wollongong, Wollongong, NSW, Australia.

Gang Chen (G)

Centre for Health Economics, Monash University, Monash Business School, Melbourne, Australia. gang.chen@monash.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH